Axelyf is developing RNA therapeutics that address diseases where conventional approaches have fallen short. Our focus is on building and advancing proprietary drug candidates — starting with AX-004, our lead in vivo CAR-T program targeting solid tumors, and AX-003, targeting autoimmune hepatitis. Both programs are enabled by the AXL platform: a next-generation lipid nanoparticle delivery system validated in non-human primates and optimized with the help of ANNA™, our proprietary AI model for lipid design.